Patents Assigned to MedImmune Oncology, Inc.
-
Patent number: 7368440Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.Type: GrantFiled: February 8, 2006Date of Patent: May 6, 2008Assignee: Medimmune Oncology, Inc.Inventors: David Cassatt, Christine A. Fazenbaker
-
Patent number: 7105575Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: May 3, 2002Date of Patent: September 12, 2006Assignee: Medimmune Oncology Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 7053072Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.Type: GrantFiled: May 8, 2002Date of Patent: May 30, 2006Assignee: Medimmune Oncology, Inc.Inventors: David Cassatt, Christine A. Fazenbaker
-
Patent number: 6841545Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.Type: GrantFiled: March 29, 2002Date of Patent: January 11, 2005Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Patent number: 6753323Abstract: The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment and prevention of infections associated with mucositis by topical application of amifostine and related compounds.Type: GrantFiled: March 28, 2001Date of Patent: June 22, 2004Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Jean Bourhis
-
Publication number: 20030216418Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.Type: ApplicationFiled: June 10, 2003Publication date: November 20, 2003Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Publication number: 20030199694Abstract: The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P{overscore (1)}(#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.Type: ApplicationFiled: December 2, 2002Publication date: October 23, 2003Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Ingomar Grafe, Johann Morsdorf
-
Patent number: 6586476Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: October 28, 1999Date of Patent: July 1, 2003Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 6576635Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.Type: GrantFiled: May 21, 2001Date of Patent: June 10, 2003Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Patent number: 6573253Abstract: The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.Type: GrantFiled: February 5, 2001Date of Patent: June 3, 2003Assignee: MedImmune Oncology Inc.Inventor: Martin Stogniew
-
Publication number: 20030022867Abstract: The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment and prevention of infections associated with mucositis by topical application of amifostine and related compounds.Type: ApplicationFiled: March 28, 2001Publication date: January 30, 2003Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Jean Bourhis
-
Patent number: 6489312Abstract: The present invention provides novel pharmaceutical compositions comprising aminoalkyl phosphorothioate compounds in combination with surfactants, hydrotropes and chelating agents. The compositions are well-suited for subcutaneous administration.Type: GrantFiled: June 15, 1999Date of Patent: December 3, 2002Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Publication number: 20020147180Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.Type: ApplicationFiled: March 29, 2002Publication date: October 10, 2002Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Publication number: 20020107393Abstract: The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P{overscore (1)} (#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.Type: ApplicationFiled: June 18, 2001Publication date: August 8, 2002Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Ingomar Grafe, Johann Morsdorf
-
Patent number: 6407278Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.Type: GrantFiled: November 16, 1998Date of Patent: June 18, 2002Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Patent number: 6384259Abstract: The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.Type: GrantFiled: November 16, 1999Date of Patent: May 7, 2002Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Publication number: 20020035093Abstract: The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.Type: ApplicationFiled: February 5, 2001Publication date: March 21, 2002Applicant: MedImmune Oncology, Inc.Inventor: Martin Stogniew
-
Publication number: 20010031755Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.Type: ApplicationFiled: May 21, 2001Publication date: October 18, 2001Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Patent number: 6258821Abstract: This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of diseases in mammals such as, but not limited to, cancer, bacterial and protozoal infections, malaria, psoriasis, and rheumatoid arthritis. The invention is further related to methods of stabilizing trimetrexate to degradation caused by heat, light, oxygen, or water.Type: GrantFiled: April 26, 1999Date of Patent: July 10, 2001Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Patent number: 6258952Abstract: The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P{overscore (1)}(#2) and having a triclinic cell with dimensions of about a=7.699 Å, b=9.606 Å and c=13.012 Å is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.Type: GrantFiled: November 9, 1999Date of Patent: July 10, 2001Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Ingomar Grafe, Johann Mörsdorf